These investigations were supported by Public Health Service grants U10-CA-37377 and U10-CA-69974 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
Version of Record online: 31 DEC 2008
Copyright © 1999 American Cancer Society
CA: A Cancer Journal for Clinicians
Volume 49, Issue 3, pages 159–177, May/June 1999
How to Cite
Fisher, B. (1999), Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA: A Cancer Journal for Clinicians, 49: 159–177. doi: 10.3322/canjclin.49.3.159
The author wishes to acknowledge the contribution of the following NSABP bio statisticians who were responsible for the data included in this review: Drs. Ann Brown, James Bryant, Joseph P. Costantino, James Dignam, Carol K. Redmond, and Samuel Wieand.
He also wishes to thank Tanya Spewock for editorial assistance, Mary Hof for preparation of the manuscript, and Jean Coyle and Christine Rudock for preparation of the graphics.
This article is also available online at http://www.ca-journal.org.
- Issue online: 31 DEC 2008
- Version of Record online: 31 DEC 2008
- 5The interdependence of laboratory and clinical research in the study of metastases, in , MilesL (eds): Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York, Raven Press, 1984, pp 27–46.:
- 11Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 1982–1992., , , et al: